Omjara tablets 200mg, manufactured by GlaxoSmithKline, contains Momelotinib hydrochloride (YJ code: 4291083F3025, standard: 200mg x 1 tablet). This novel JAK1/JAK2/ACVR1 inhibitor is indicated for adults with intermediate or high-risk myelofibrosis and anemia. It works by suppressing the hyperactive JAK-STAT pathway and improving anemia through ACVR1 inhibition, providing a comprehensive treatment approach.
Omjara tablets 200mg
Need more detailed information?
Contact TASAKI PHARMA for inquiries about this medicine (English support available).
Contact us about this drug →
